Spiro-medical

Spiro Medical operates at the intersection of medical devices, respiratory medicine, clinical research, and neuromodulation. Its proposed differentiation is an implantable Pulmonary Neuromodulation System designed to address neurological mechanisms associated with severe respiratory disease and provide a drug-free option for patients with severe, uncontrolled asthma. That places the company in a specialized, clinically demanding segment rather than the broad consumer respiratory-device market. The $67 million Series A, led by Andera Partners and backed by six additional investors, represents meaningful financing for a company founded in 2023 and supports continued development of its clinical-stage platform. The company’s potential advantage is the use of neuromodulation to target respiratory disease biology through an implantable system; its principal market risks are clinical validation, procedural adoption, reimbursement, and regulatory approval.

Spiro Medical’s trajectory shows a rapid transition from formation to substantial clinical-stage financing. The company was founded on Jan 1, 2023, and Stephen T. Pyles is listed as a co-founder. Its first and only disclosed financing is a $67 million Series A announced on Jan 7, 2026, led by Andera Partners with six other participating investors. The round is the clearest inflection point in the company’s development, providing resources to progress the Spiro Neuromodulation System for severe, uncontrolled asthma and other severe respiratory conditions. The appointment of Emilie Finiels as Head of Business Development on Jan 1, 2026 adds a commercial-development capability shortly before the financing announcement. Current staffing remains lean, with two listed positions and an employee range of 11–50, suggesting the company is still building the organization needed for clinical execution, regulatory work, manufacturing, and future market access. No layoffs are reported, but there is no quantified hiring trend, product-launch history, regulatory milestone, or disclosed revenue. Growth therefore appears financing-led and development-focused rather than yet demonstrated through commercialization.